Trends in antidiabetic drug use in Portugal: 8 years real‐world data from a nationwide retrospective observational study (2017–2024) ( TREND ‐8 study)

João Sérgio Neves reports having received consulting or speaker fees from AstraZeneca, Bayer, BIAL – Portela & CA, S.A., Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Menarini, Merck, and Sanofi. Ana Rita Leite reports having received consulting fees from BIAL – Portela & CA, S.A. Mafalda Marcelino reports having received consulting or speaker fees from AstraZeneca, BIAL – Portela & CA, Boehringer Ingelheim, Eli Lilly, Merck, MSD, Novartis, Sanofi, and Novo Nordisk. Miguel Melo reports having received consulting or speaker fees from Abbott, Astra-Zeneca, Bayer, BIAL – Portela & CA, Boehringer-Ingelheim, Janssen, Lilly, Novo-Nordisk, Roche, Sanofi/Genzyme. Paula Freitas reports having received speaker fees from Amryt, AstraZeneca, BIAL – Portela & CA, S.A., Boehringer-Ingelheim, Gilead Sciences, Janssen, Lilly, MSD, Merck, S.A., Novartis, Novo Nordisk, Pronokal, Sanofi; and consulting fees from AstraZeneca, Janssen, Lilly, MSD, Novo Nordisk, Pronokal. Célia Ramalho is an employee of BIAL – Portela & CA, S.A. Eduardo Calçada is an employee of BIAL – Portela & CA, S.A. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.16429. The datasets generated and/or used in this study are managed by Health Market Research and are not publicly available. However, they may be made available upon reasonable request. Further inquiries can be directed to the corresponding author. Appendix S1. Codes and definitions used in this study. Appendix S2. Variation on the (A) total antidiabetic drugs dispensed and (B) prescription proportion by drug and ATC4 class, between 2017 and 2024 in Portugal. Appendix S3. Variation on the (A) total antidiabetic drugs dispensed and (B) prescription proportion by drug class, between 2017 and 2024 in Portugal across the main medical specialties involved in type 2 diabetes management. Appendix S4. Distribution of total antidiabetic drug prescriptions by medical specialty in Portugal from 2017 to 2024. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.